针对老鼠心脏病发作后心力衰竭的最佳治疗方法是:先给大巴格利弗洛,然后在2周后再添加萨库比特里尔-瓦尔萨坦
Wenqi Tao1, Xiaoyu Yang2,3, Qing Zhang4
1Tianjin Union Medical Center, Tianjin Medical University, Tianjin, China.
Frontiers in cardiovascular medicine
|June 29, 2023
概括
早期的达帕格利弗洛辛 (DAPA) 随后的萨库比特里尔-瓦尔萨坦 (S/V) 在肌肉中风后心力衰竭 (后MI HF) 鼠群中显著改善了心脏功能. 在急性心肌梗塞后太早结合DAPA和S/V增加了死亡率.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 翻译医学是一种翻译医学.
背景情况:
- 心力衰竭 (HF) 管理受益于达帕格利弗洛辛 (DAPA) 和萨库比特里尔-瓦尔萨坦 (S/V).
- 心肌梗塞后心力衰竭 (心肌梗塞后心力衰竭) 需要优化治疗策略.
- 研究DAPA和S/V的顺序与单一疗法对改善心脏功能至关重要.
研究的目的:
- 为了比较早期DAPA启动与S/V单疗法的疗效,在后MI HF.
- 评估DAPA和S/V连续给药对心脏功能的影响.
- 为了确定在后MI HF模型中将DAPA和S/V结合在一起的最佳时间.
主要方法:
- 建立了小鼠心肌梗塞 (MI) 的模型.
- 随机分成六组,包括虚假,MI,MI + S/V (1日),MI + DAPA (1日),MI + S/V (1日) + DAPA (14日),以及MI + DAPA (1日) + S/V (14日).
- 评估心脏结构和功能使用组织学,西式涂抹和RNA-seq.
主要成果:
- 无论是DAPA还是S/V单疗法,都显示了心脏结构和功能的可比改善.
- 与其他治疗组相比,随着DAPA和S/V的连续使用,产生了优越的心脏保护作用.
- 早期组合疗法在急性心脏病发作后3天内显著增加死亡率.
结论:
- 随着DAPA之后的S / V是后MIHF的更有效的策略,而不是S / V单疗法或随着DAPA后的顺序S / V.
- 用DAPA或S/V单一治疗显示,在心脏病发作后的高心力衰竭中,心脏保护作用类似.
- 组合治疗的时间是关键的,早期管理后AMI与增加的死亡率有关.
更多相关视频
09:11Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix
Published on: September 22, 2014
12.0K
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
8.6K
相关概念视频
01:30Heart Failure V: Medical Management
15
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
15
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
467
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
467
01:26Heart Failure Drugs: Inotropic Agents
640
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
640
01:22Heart Failure VI: Adjunct Therapies
16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
01:22Heart Failure Drugs: Diuretics
425
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
425
01:22Heart Failure Drugs: β-Blockers
371
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
371